Traceability of Biologics in The Netherlands: An Analysis of Information-Recording Systems in Clinical Practice and Spontaneous ADR Reports

INTRODUCTION AND OBJECTIVE: Pharmacovigilance requirements for biologics mandate that EU Member States shall ensure that any biologic that is the subject of a suspected adverse drug reaction (ADR) is identifiable by brand name and batch number. Recent studies showed that brand name identification is...

Descripción completa

Detalles Bibliográficos
Autores principales: Klein, Kevin, Scholl, Joep H. G., Vermeer, Niels S., Broekmans, André W., Van Puijenbroek, Eugène P., De Bruin, Marie L., Stolk, Pieter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2015
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4735237/
https://www.ncbi.nlm.nih.gov/pubmed/26719190
http://dx.doi.org/10.1007/s40264-015-0383-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4735237/
https://www.ncbi.nlm.nih.gov/pubmed/26719190
http://dx.doi.org/10.1007/s40264-015-0383-8

Ejemplares similares